EP Patent

EP3256495A4 — Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins

Assigned to Aptevo Research and Development LLC · Expires 2018-09-19 · 8y expired

What this patent protects

Patent listed against Xtandi.

Drugs covered by this patent

Patent Metadata

Patent number
EP3256495A4
Jurisdiction
EP
Classification
—
Expires
2018-09-19
Drug substance claim
No
Drug product claim
No
Assignee
Aptevo Research and Development LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.